JP2012521364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521364A5 JP2012521364A5 JP2012501029A JP2012501029A JP2012521364A5 JP 2012521364 A5 JP2012521364 A5 JP 2012521364A5 JP 2012501029 A JP2012501029 A JP 2012501029A JP 2012501029 A JP2012501029 A JP 2012501029A JP 2012521364 A5 JP2012521364 A5 JP 2012521364A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- circadian rhythm
- derivative
- ampk
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 28
- 230000027288 circadian rhythm Effects 0.000 claims description 17
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 15
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 12
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 claims description 10
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 238000007917 intracranial administration Methods 0.000 claims description 7
- 239000007927 intramuscular injection Substances 0.000 claims description 7
- 238000010255 intramuscular injection Methods 0.000 claims description 7
- 238000010253 intravenous injection Methods 0.000 claims description 7
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 239000000829 suppository Substances 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- 102000002281 Adenylate kinase Human genes 0.000 claims description 5
- 108020000543 Adenylate kinase Proteins 0.000 claims description 5
- 102000011690 Adiponectin Human genes 0.000 claims description 5
- 108010076365 Adiponectin Proteins 0.000 claims description 5
- 102000016267 Leptin Human genes 0.000 claims description 5
- 108010092277 Leptin Proteins 0.000 claims description 5
- 150000004283 biguanides Chemical group 0.000 claims description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 5
- 229940039781 leptin Drugs 0.000 claims description 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 5
- 229960003105 metformin Drugs 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 5
- 229960003243 phenformin Drugs 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000006399 behavior Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000013543 active substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16222509P | 2009-03-20 | 2009-03-20 | |
| US61/162,225 | 2009-03-20 | ||
| PCT/US2010/028155 WO2010108179A1 (en) | 2009-03-20 | 2010-03-22 | Methods for modulating circadian rythms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012521364A JP2012521364A (ja) | 2012-09-13 |
| JP2012521364A5 true JP2012521364A5 (enExample) | 2013-05-09 |
Family
ID=42740034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501029A Pending JP2012521364A (ja) | 2009-03-20 | 2010-03-22 | 概日リズムを調整する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120264796A1 (enExample) |
| EP (1) | EP2409152A4 (enExample) |
| JP (1) | JP2012521364A (enExample) |
| AU (1) | AU2010226417A1 (enExample) |
| CA (1) | CA2753876A1 (enExample) |
| WO (1) | WO2010108179A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010226386A1 (en) * | 2009-03-20 | 2011-10-13 | The Salk Institute For Biological Studies | Methods for modulating metabolic and circadian rhythms |
| US20140186306A1 (en) * | 2012-09-28 | 2014-07-03 | Paul Ronald Plante | Novel ampk agonist compositions and methods of use |
| US10572904B2 (en) | 2017-03-29 | 2020-02-25 | International Business Machines Corporation | Micro circadian rhythms driven dynamic product offering adjustment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3466215D1 (en) * | 1983-05-18 | 1987-10-22 | Univ Monash | The use of melatonin for the manufacture of a medicament |
| US20060147947A1 (en) * | 2002-12-04 | 2006-07-06 | Javier Apfeld | AMPK pathway components |
| EP1696959A2 (en) * | 2003-12-24 | 2006-09-06 | Sepracor, Inc. | Melatonin combination therapy for improving sleep quality |
| EP1986663A2 (en) * | 2006-01-16 | 2008-11-05 | The Board of Regents of The University of Texas System | Adenosine monophosphate for inducing torpor in a subject |
| TWI428767B (zh) * | 2006-06-26 | 2014-03-01 | Ibm | 最佳化配置系統參數集之方法，程式及裝置 |
| KR100766273B1 (ko) * | 2006-10-23 | 2007-10-15 | 주식회사 녹십자 | 아디포넥틴을 유효 성분으로 포함하는 프라더-윌리 증후군소아용 수면 장애 치료제 |
| WO2008097861A2 (en) * | 2007-02-02 | 2008-08-14 | Braincells, Inc. | MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS |
| AU2008345009A1 (en) * | 2007-12-28 | 2009-07-09 | The Salk Institute For Biological Studies | Methods for enhancing muscle performance and tone |
-
2010
- 2010-03-22 JP JP2012501029A patent/JP2012521364A/ja active Pending
- 2010-03-22 WO PCT/US2010/028155 patent/WO2010108179A1/en not_active Ceased
- 2010-03-22 CA CA2753876A patent/CA2753876A1/en not_active Abandoned
- 2010-03-22 AU AU2010226417A patent/AU2010226417A1/en not_active Abandoned
- 2010-03-22 EP EP10754232A patent/EP2409152A4/en not_active Withdrawn
- 2010-03-22 US US13/257,745 patent/US20120264796A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2506717B1 (en) | Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions | |
| Shin et al. | Preanesthetic dexmedetomidine 1 µg/kg single infusion is a simple, easy, and economic adjuvant for general anesthesia | |
| Ünlügenç et al. | A comparative study on the analgesic effect of tramadol, tramadol plus magnesium, and tramadol plus ketamine for postoperative pain management after major abdominal surgery | |
| EA022119B1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений - ингибиторов hsp90 | |
| Staal et al. | Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata | |
| Koç et al. | The preoperative use of gabapentin, dexamethasone, and their combination in varicocele surgery: a randomized controlled trial | |
| JP2010530431A5 (enExample) | ||
| CA2443229A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv | |
| KR20110028651A (ko) | (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물 | |
| Shortall et al. | Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone | |
| AU2002244860A1 (en) | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV | |
| JP2012521198A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| ES2775425T3 (es) | Procedimiento de tratamiento del síndrome de Prader-Willi | |
| US12311056B2 (en) | Composition and method for treatment of neuropsychiatric disorders | |
| Feistel et al. | The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion | |
| Sahin et al. | Comparison between low flow sevoflurane anesthesia and total intravenous anesthesia during intermediate-duration surgery: effects on renal and hepatic toxicity | |
| Uysal et al. | The effects of dexmedetomidine on hemodynamic responses to tracheal ntubation in hypertensive patients: A comparison with esmolol and sufentanyl | |
| BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
| JP2012521364A5 (enExample) | ||
| Menshawi et al. | Dexmedetomidine versus lidocaine as an adjuvant to general anesthesia for elective abdominal gynecological surgeries | |
| WO2013029006A1 (en) | Dengue virus and yellow fever virus therapies | |
| Dutta et al. | Indian red scorpion venom-induced augmentation of cardio-respiratory reflexes and pulmonary edema involve the release of histamine | |
| WO2025123235A1 (zh) | 一种治疗或预防甲基苯丙胺成瘾的药物及应用 | |
| Hess et al. | Experience with a naphthylmedetomidine–ketamine–hyaluronidase combination in inducing immobilization in anthropoid apes |